Marksans Pharma Limited has informed the Exchange regarding a press release dated November 20, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution".